UCB (OTCMKTS:UCBJF) Trading Down 5.8% – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) was down 5.8% during trading on Thursday . The company traded as low as $289.00 and last traded at $289.00. Approximately 116 shares were traded during trading, a decline of 85% from the average daily volume of 783 shares. The stock had previously closed at $306.94.

Wall Street Analyst Weigh In

UCBJF has been the topic of a number of recent research reports. Wolfe Research began coverage on shares of UCB in a research note on Monday, February 23rd. They set an “outperform” rating on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research report on Monday, February 16th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy”.

UCB Price Performance

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average price is $294.32 and its two-hundred day moving average price is $297.16.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.